Barclays PLC Keros Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 60,014 shares of KROS stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,014

Previous 60,014 -0.0%

Holding current value

$1.02 Million

Previous $3.48 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$41.68 - $58.07 $1.46 Million - $2.03 Million	35,022 Added 140.13%	60,014 $3.48 Million
Q2 2024 Aug 14, 2024	SELL	$44.58 - $66.89 $1.99 Million - $2.99 Million	-44,664 Reduced 64.12%	24,992 $1.14 Million
Q1 2024 May 15, 2024	SELL	$41.26 - $70.48 $7.84 Million - $13.4 Million	-190,104 Reduced 73.18%	69,656 $4.61 Million
Q4 2023 Feb 15, 2024	BUY	$27.12 - $41.05 $5.7 Million - $8.63 Million	210,249 Added 424.65%	259,760 $10.3 Million
Q3 2023 Nov 07, 2023	BUY	$31.57 - $43.02 $350,995 - $478,296	11,118 Added 28.96%	49,511 $1.58 Million
Q2 2023 Aug 03, 2023	BUY	$37.26 - $51.01 $337,091 - $461,487	9,047 Added 30.83%	38,393 $1.54 Million
Q1 2023 May 04, 2023	SELL	$41.44 - $59.32 $355,928 - $509,499	-8,589 Reduced 22.64%	29,346 $1.25 Million
Q4 2022 Feb 13, 2023	SELL	$39.45 - $51.77 $2.35 Million - $3.09 Million	-59,640 Reduced 61.12%	37,935 $1.82 Million
Q3 2022 Nov 03, 2022	BUY	$27.8 - $40.12 $1.77 Million - $2.55 Million	63,658 Added 187.69%	97,575 $3.67 Million
Q2 2022 Aug 12, 2022	BUY	$26.03 - $67.04 $551,757 - $1.42 Million	21,197 Added 166.64%	33,917 $936,000
Q1 2022 May 16, 2022	BUY	$42.12 - $59.36 $535,766 - $755,059	12,720 New	12,720 $691,000

Others Institutions Holding KROS

# of Institutions

174

Shares Held

30.3M

Call Options Held

76.8K

Put Options Held

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $439M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account